Mecolvix

Mesalazine, the active ingredient in Mecolvix, is an aminosalicylate presented as an oral formulation for oral use. It is employed to treat inflammatory bowel conditions such as ulcerative colitis and mild Crohn's disease, helping to reduce intestinal inflammation.

GNH USA supplies Mecolvix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mecolvix, an aminosalicylate, is used in the management of inflammatory bowel disease.

Ulcerative colitis: induces remission of active disease. Maintenance of remission in ulcerative colitis: helps sustain symptom‑free periods. Mild Crohn's disease (colonic): reduces intestinal inflammation and promotes clinical improvement.

Mesalazine may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Nausea or upset stomach. - Headache. - Abdominal pain or cramping. - Skin rash or mild itching.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis, angioedema). - Blood disorders such as neutropenia or thrombocytopenia. - Acute pancreatitis. - Kidney injury or interstitial nephritis. - Liver dysfunction or hepatitis.

Before initiating Mecolvix, several safety considerations should be observed.

Monitor renal function: assess kidney parameters regularly. Monitor hepatic function: check liver enzymes during therapy. Assess disease activity: ensure appropriate indication before use. Avoid in known hypersensitivity: discontinue if allergic signs appear. Use with caution in pregnancy: safety data are limited; evaluate risk‑benefit. Store at room temperature: keep in the original container, protect from moisture.

Mesalazine can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Azathioprine or 6‑mercaptopurine: may increase risk of bone‑marrow suppression. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): can raise the chance of renal impairment.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): may enhance anticoagulant effect. - Digoxin: potential increase in serum levels. - Oral contraceptives: possible reduction in contraceptive efficacy.